The Centers for Medicare and Medicaid Services ("CMS") published a final notice outlining the processes and procedures for the Transitional
The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input f | The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program.
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of
Senators grilled Robert F. Kennedy Jr. on if and how he would reform Medicaid and Medicare during his first confirmation hearing to become the next secretary of Health and Human Services.
In 2025, we may see radical top-down changes to our healthcare system as new heads of the NIH – National Institutes of Health, HHS – Health and Human Services; the CDC – Center for Disease Control and Prevention.
CMS ultimately selected to test three models with the ... would have had Medicare pay less for drugs that receive accelerated approvals from the Food and Drug Administration (FDA). The FDA grants accelerated approvals to promising drugs to make them ...
Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle drug pricing reforms
Biden-era policies rescinded by Donald Trump could signal a significant shake-up in Medicare and Medicaid drug price reforms.
Robert F. Kennedy Jr. said he would follow the Trump administration’s orders on prescription drug price negotiations, a process that is overseen by the Centers for Medicare and Medicaid Services. He said he would focus on fighting chronic disease,
The U.S. Centers for Medicare & Medicaid Services, or CMS, said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation Reduction Act of 2022.
When combined with the first round of negotiation, it is clear that the success of the Medicare drug negotiation program has been nothing short of remarkable,” CMS Administrator Chiquita Brooks-LaSure said. Senior administration officials declined to ...